ClinicalTrials.gg
RecruitingNCT07381413TAO-AUpdated Feb 6, 2026

Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmopathy

An observational study in Thyroid Associated Ophthalmopathies and Eye Tracking, sponsored by Shanghai Changzheng Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Shanghai Changzheng Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Planned enrollment
6th of 10
100 · median 125
Started
2026
with 10 others
Observational
10 of 55
5 open now
Primary completion
2029-05
later than 26 of 27 live
Registered
47th of 55
by date
Lead sponsor
6 of 55
Shanghai Changzheng Hospital

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 6th largest by planned enrollment of the 10 observational ones that give a count, is one of 11 that started in 2026, is one of 10 observational ones, reaches primary completion later than 26 of the 27 other live ones, and was the 47th registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 17 (44%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

This study focuses on eye health and visual function in patients with Thyroid-Associated Ophthalmopathy (TAO), a condition that often causes bulging eyes and restricted eye movement. The purpose of this study is to use non-invasive eye-tracking technology to evaluate how the disease affects eye movement function. The investigators hypothesize that compared to healthy individuals, patients with TAO will show measurable differences in eye stability and the ability to track moving objects. Additionally, the investigators believe the disease may alter how patients visually scan faces (e.g., avoiding eye contact). The study will enroll 100 participants, including both patients and healthy volunteers. By recording gaze patterns while participants look at a screen, the investigators aim to objectively quantify the physical and social impact of the disease, providing better data for future treatment plans.

03

Conditions studied

  • Thyroid Associated Ophthalmopathies
  • Eye Tracking

Browse trials for

Keywords

  • TAO
  • eye tracking
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The Thyroid-Associated Ophthalmopathy (TAO) group will consist of consecutive patients presenting to the clinic who are diagnosed with TAO according to the 2022 Chinese Guidelines for the Diagnosis and Treatment of Thyroid-Associated Ophthalmopathy. The healthy control group will be recruited through hospital staff volunteers and community advertisements.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 70 years, inclusive.
  • Willing and able to provide written .
  • Best-corrected visual acuity (BCVA) ≥ 1.0 in both eyes, with no history of ocular diseases or thyroid disorders.

Exclusion criteria

Exclusion Criteria:

  • Non-TAO Ocular Motility Disorders: History of conditions like myasthenia gravis, cranial nerve palsy, or congenital strabismus.
  • Neurological Diseases: Disorders affecting oculomotor control (e.g., Parkinson's, MS, stroke, or brain tumors).
  • Significant Visual Impairment: BCVA \< 0.5 due to media opacities or retinopathy, preventing clear visualization of stimuli.
  • Prior Ocular Surgery: History of surgeries affecting extraocular muscle mechanics (e.g., strabismus surgery, scleral buckling).
  • Psychiatric or Cognitive Disorders: Inability to follow instructions or conditions affecting eye movements (e.g., schizophrenia).
  • Medication Interference: Use of drugs affecting reaction time (e.g., sedatives) within 48 hours of testing.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • TAO

    Device: Non-invasive Eye Tracking Assessment

  • CON

    Device: Non-invasive Eye Tracking Assessment

Interventions

  • DeviceNon-invasive Eye Tracking Assessment

    This is an observational study; no therapeutic intervention is administered. All participants undergo a single, standardized study visit that includes: Participants will undergo a visual function assessment using a desktop-based high-frequency eye tracker. The assessment consists of three parts: 1. Calibration: To ensure accurate gaze tracking. 2. Oculomotor Tasks: Participants track visual targets to measure fixation stability and smooth pursuit capabilities. 3. Visual Attention Tasks: Participants view static images to record scanning patterns. The entire process is non-invasive and lasts approximately 15-20 minutes.

06

What researchers measure

Primary outcomes

  1. Smooth Pursuit Function Gaze Distribution

    Participants track a moving target on the screen. This metric quantifies the spatial distribution of fixation points recorded throughout the task duration

    Time frame: Baseline

Secondary outcomes

  1. Central Fixation Stability

    This outcome measures the participant's ability to maintain a steady gaze on a central target for a predefined duration. It is quantified by the percentage of fixation time remaining within a small predefined area around the target center.

    Time frame: Baseline

  2. Gaze Distribution on Ocular Areas of Interest

    This metric analyzes the visual attention patterns when viewing images.This is used to evaluate potential social-visual avoidance or altered scanning strategies in TAO patients compared to healthy controls.

    Time frame: Baseline

  3. Extraocular Muscle (EOM) Thickness

    The thickness of the extraocular muscles (including the medial, lateral, superior, and inferior rectus). This anatomical metric serves as a biological marker of disease severity and will be correlated with eye-tracking functional data to explore the relationship between muscle hypertrophy and movement impairment.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yang C, Shen Y, Song J, Chen Y, Zeng C, Wei R. Clinically accessible eye-tracking in thyroid-associated ophthalmopathy: exploratory classification modeling and gaze allocation to disease-related periocular images. BMC Ophthalmol. 2026 Jun 22. doi: 10.1186/s12886-026-05055-6. Online ahead of print. PubMed 42332638 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2029, 40 months after the start.

Of 21 observational studies under Graves Ophthalmopathy, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 59. This study's planned 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2026
First posted
Feb 2, 2026
StartActual
Jan 31, 2026
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07381413
Responsible party
Ruili Wei (Chief of Ophthalmology, Shanghai Changzheng Hospital) — Principal investigator
First posted
Feb 2, 2026
Start date
Jan 31, 2026
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Feb 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion